Johnson & Johnson's ($JNJ) new Prezista formulation, a once-daily 800 mg pill, won approval from European regulators. The FDA gave its blessing to the new HIV drug in November. The original Prezista is set to lose exclusivity in 2017. Report
| SPONSORED BY: Appian | Wednesday, August 12th | 11am ET / 8am PT
Pharma companies can employ several strategies for obtaining expedited approvals-including, in some cases, acquiring them from other companies. This webinar will feature regulatory experts from the pharma industry who can provide tips on navigating these programs. Register Today!
FiercePharma is the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Join 150,000+ pharma industry leaders who get FiercePharma via daily email. Click here to get your free weekly email briefing today!